MERIEUX EQUITY PARTNERS ACQUIRES MAJORITY STAKE IN PLANTEX, VIA ITS MERIEUX PARTICIPATIONS 3 VEHICLE
Plantex is a French manufacturer of high quality natural plant extracts for nutraceutical, dietary, animal nutritional and cosmetic purposes.
Merieux Equity Partners invests in Laboratoires CTRS alongside the Management Team, via its Merieux Participations 3 vehicle.
CTRS is a French pharmaceutical company that develops and markets treatments for patients with strong unmet medical needs, with a particular focus on orphan diseases.
Cell-Easy announces the completion of a financing round to accelerate its growth trajectory in the cell therapy sector, with Merieux Equity Partners as lead investor and reference shareholder
Cell-Easy is a stem cell Contract Development and Manufacturing Organization (CDMO) that provides ready-to-inject adipose-derived allogeneic stem cells for preclinical and clinical drug development.
BIOBEST acquires ownership of Beneficial Insectary Inc. of California
Beneficial Insectary Inc. is North America's largest independent producer of beneficial insects and mites.
CEVA becomes first animal health company to be awarded "Animal Welfare-Friendly" certification by Brazil's dairy sector
Two products were approved by the Welfare Scheme - Velactis and Ketofen.
SEQENS invests in new technologies and is committed to producing essential molecules to secure the supply chain of critical essential drugs substances at 5 of its industrial facilities
To carry out these projects, Seqens relies on the SEQENS’Lab, its R&D center, and on four of its APIs and pharmaceutical intermediates production sites and a total investment of €65 million.
XERIS PHARMACEUTICALS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS
Gvoke® net sales grew 370% quarter over quarter to $9.4 million driven by launch of Gvoke HypoPen®.
ProDigest and Biofortis announce an agreement for a global collaboration in the field of gastrointestinal research
This Agreement will enable a combination of the know-how in preclinical testing developed by ProDigest and the expertise in clinical trials and microbiome analysis of Biofortis.
CEVA BUILDS ON ITS PREVENTATIVE HEALTH STRATEGY WITH OPENING OF A NEW EUROPEAN REFERENCE FOR THE MANUFACTURE OF AUTOGENOUS VACCINES
This €8 million innovative project confirms Ceva’s commitment to improving preventative animal health and reducing the use of antibiotics. The addition to the existing Ceva Biovac site will further reinforce Ceva as the leading provider of autogenous vaccines for animals.